SAN MATEO, Calif.
/PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that
, President and Chief Executive Officer, is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference 2010, to be held
Thursday, April 8, 2010
at the Millennium Broadway Hotel & Conference Center in
New York, New York
Mr. DiTonno and
, Executive Vice President, Chief Operating Officer and Chief Financial Officer, will be available to respond to questions during a breakout session immediately following the presentation, and to participate in one-on-one meetings with investors attending the conferences.
: BioCentury Future Leaders in the Biotech Industry Conference 2010
Thursday, April 8, 2010
: The Millennium Broadway Hotel & Conference Center,
New York, NY
The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at
. The webcast will be archived for 90 days.
NASDAQ Opening Bell Ceremony: April 6, 2010
Mr. DiTonno, along with members of the NeurogesX management and sales teams, will ring the ceremonial market opening bell at the NASDAQ Stock Market at
9:30 a.m. ET
Tuesday, April 6, 2010
A live webcast of the NASDAQ opening bell will be available at:
, where it will be archived for one year.
About NeurogesX, Inc.
NeurogesX, Inc. (Nasdaq: NGSX) is a
San Francisco Bay Area
-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.
The Company's lead product, Qutenza® (capsaicin) 8% patch, is a localized dermal delivery system containing a prescription strength of capsaicin that is currently approved in
the United States
and the European Union. NeurogesX expects to launch Qutenza in
for patients with postherpetic neuralgia (PHN). In
, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of
-based Astellas Pharma Inc.
The Company's most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.